AI-Based Mobile Intervention on Medication Non-Adherence and Transition (NCT07445074) | Clinical Trial Compass
RecruitingNot Applicable
AI-Based Mobile Intervention on Medication Non-Adherence and Transition
United States200 participantsStarted 2026-05
Plain-language summary
This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in Florida, USA.
Outcomes are organized into primary (effectiveness), secondary (usability), and exploratory (language experience) endpoints.
Who can participate
Age range
14 Years – 24 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosed with epilepsy
* Currently prescribed anti-seizure medicine (ASMs)
* Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically underrepresented in research or healthcare or low-income status (e.g., eligible for public assistance or government-subsidized health coverage)
* Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study
* Are between 18-24 years old and able to provide informed consent
* Able to read, speak, and write in English
* Resides in Florida
* Receive outpatient medical services
Exclusion Criteria:
* They do not own a mobile device with internet access.
* They have a history of severe intellectual disability.
* They are unable to operate a mobile device (keyboard or touchscreen).
* Reside in an in-patient setting.
* Adults unable to consent.
* Pregnant women (excluded because pregnancy is not relevant to the study focus).
* Prisoners.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Examine the effect of Medilepsy® with and without responsible AI design on medication adherence.